Business
COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that the European Patent and Trademark Office has allowed a patent application related to CollPlant's injectable fillers and regenerative breast implant candidates, being developed for the aesthetic and reconstructive procedures markets, respectively.
About this update from Collplant Biotechnologies Ltd.
[{"type":"text","content":"- Further protection granted in key territory applying to the significant and growing aesthetic and reconstructive markets - ","length":124,"tagName":"p"},{"type":"text","content":"REHOVOT, Israel, June 4, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that the European Patent and Trademark Office has allowed a patent application related to CollPlant's injectable fillers and regenerative breast implant candidates, being developed for the aesthetic and reconstructive procedures markets, respectively.","length":551,"tagName":"p"},{"type":"image","alt":"A 200cc commercial-size breast implant (in front) from CollPlant’s regenerative program","displaySize":"","headline":null,"caption":"A 200cc commercial-size breast implant (in front) from CollPlant’s regenerative program","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":309,"url":"https://media.zenfs.com/en/prnewswire.com/64ba1a39fabe977de9d8f8b9a7a0ac63"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0PB42Eq7dt49E34UH93ESw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTU0NTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/64ba1a39fabe977de9d8f8b9a7a0ac63","width":400,"height":309}},"href":"https://mma.prnewswire.com/media/2703101/CollPlant.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"This newly allowed patent application pertains to CollPlant's injectable soft tissue fillers as well as its organ manufacturing technology related to its regenerative breast implant pipeline currently under development. The European Patent Application is directed, among other things, to a 3D biocompatible and degradable soft tissue implant composed of a bioprinted scaffold and an injectable filler within it, each based on its recombinant human collagen (rhCollagen).","length":484,"tagName":"p"},{"type":"text","content":"Yehiel Tal, CollPlant's Chief Executive Officer, commented, "This patent, effective until 2041, represents an integral part of the Company's strategy to expand the uses for its novel, rhCollagen technology into new, high-value markets. The market for injectable soft-tiss...